🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ajay Nooka, MD, MPH Al Garfall Krina Patel Love the videos of a community oncologist from San Antonio adding to the Real-World vs Trial based discussion-great touch and very relatable for some who do not have close access to a #myeloma center #imfash24 #ash24 Robin Tuohy

Best #ASHaiku @JillZitzewitz #ASH24 #IMFASH24

Thank you Vincent Rajkumar and all who are doing Trials!! We need more “chemicals to become medicine” ! Great Thread #ASH24 #IMFASH24 #MMsm

Love Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 excitement and credit to junior researchers presenting at #ASH24 and Sheri Baker patient perspective! #IMFASH24 #MMsm

Etentamig (ABBV-383) very interesting features and benefits. Showing less CRS, infections still something to consider. #MMSM #Myeloma #ASH24 #IMFASH24

There were no new safety signals with combining Etentamig (ABBV-383) with Dara and Dex in patients with RRMM. #myeloma #ASH24 #IMFASH24 Thank the team that continues all the work on this!

However, the improvement in fatigue wasn’t sustained after the intervention so doing something for a few weeks isn’t going to help long term, it must be continued. Thanks Teresa Miceli. ❤️&☮️4🌎 I stole your photo. #ASH24 #imfash24

Use of #teclistimab in elder pop of #myeloma patients. ORR 63% with nearly 1y duration. MM is elder disease. MajesTEC trial had 24 pts >75y. #ASH24 #mmsm @IMFMyeloma #IMFASH24

Relapse, infection and sepsis leading causes of death. >75y had better ORR & PFS. Age should not preclude use of #teclistimab in older population. #myeloma #ASH24 #mmsm @IMFMyeloma #IMFASH24

Excellent "real world" patient perspective that is important to share. #MMSM #Myeloma #ASH24 #IMFASH24

#hellomylo is such a valuable tool. Congratulations to International Myeloma Foundation for being on the forefront of technology to assist #myeloma patients worldwide. #MMSM #ASH24 #IMFASH24

Visit myeloma.org/sparkcures to start searching today! Or get even more personalized options when you create an account on myeloma.org #ash24 #imfash24 SparkCures

Abstract 1027 Early Safety and Efficacy of CAR-T Cell Therapy in HR-SMM: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma #ASH24 #mmsm International Myeloma Foundation #IMFASH24 #myeloma

Abstract 1021 SDCC Hall B Cevostamab in heavily pretreated RRMM: Updated Results from Ongoing Phase 1 Study ⁦⁦Joshua Richter, MD, FACP⁩ “Thank you for letting me speak in this ginormous room” lol. Great Talk! #ASH24 #IMFASH24 #MMsm

Extramedullary multiple myeloma (EMM) is a HR #myeloma variant with poor outcomes, even with #CART. Abstract 1028 Ph I Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients w/ RRMM with EMM. N=8, age 18-75 #ASH24 #mmsm @IMFMyeloma #IMFASH24

Support Groups are Important! I’m 3 months into my myeloma learning journey, finally getting a hold on things and then #ASH24 goes and throws out a new target out to learn about. This is why I’m here! I Learn and translate for patients and care partners #imfash24 International Myeloma Foundation

#IMFASH24 #ASH24

Abstract 1029 CAR-T Cell Therapy in Advanced #Myeloma with Extramedullary Disease – Imaging in CARAMEL: First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI #ASH24 #mmsm @IMFMyeloma #IMFASH24

#1029 CAR-T-Advanced MM w/ Extramedullary Disease-In Vivo Imaging-Molecular Monitoring Study (CARAMEL): 1st Results Cu-64 Radiolabelled Nanoparticle PET-CT- PET-MRI-Mark R Dowling, MBBS, PhD "Criteria is simple: small enough to fit in machine as it’s in children’s hospital" LOL

Great bumping into Oya and going into next sessions! #ASH24 #IMFASH24 #MMsm